H.C. Wainwright lowered the firm’s price target on Arvinas (ARVN) to $81 from $87 and keeps a Buy rating on the shares. Given the company’s ...

H.C. Wainwright lowered the firm’s price target on Sage Therapeutics (SAGE) to $12 from $14 and keeps a Neutral rating on the shares. The ...

H.C. Wainwright adjusted its price target for Largo Resources Ltd. (NASDAQ:LGO) to $3.70, down from the previous $4.20, while maintaining a "Buy" rating on the stock. The firm's decision follows Largo ...

H.C. Wainwright analyst Scott Buck revised the price target on Yatra Online (NASDAQ:YTRA) to $3.00 from the previous $4.00, while maintaining a Buy rating on the company's stock. The adjustment ...

D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at ...

Investment analysts at HC Wainwright lowered their FY2028 earnings estimates for X4 Pharmaceuticals in a research note issued on Friday, February 7th. HC Wainwright analyst S. Ramakanth now forecasts ...

Fintel reports that on February 7, 2025, HC Wainwright & Co. initiated coverage of Vertical Aerospace (NYSE:EVTL) with a Buy recommendation. As of January 28, 2025, the average one-year price ...

We recently compiled a list of the 10 Trending AI Stocks That Analysts Are Monitoring. In this article, we are going to take ...

In 2024 H.C. Wainwright also held the top position in PlacementTracker's Market League Tables for At-the-Market (ATM) Offerings representing 72 transactions. In addition to presently serving as ...

Tuesday, H.C. Wainwright reaffirmed its Buy rating on Northern Dynasty Minerals (NYSE:NAK) with a steady price target of $1.30, representing significant upside from the current trading price of $0.65.

NEW YORK--(BUSINESS WIRE)--H.C. Wainwright & Co., LLC, announced its #1 Ranking by transaction volume for the calendar year of 2024, maintaining the Firm’s top position for 11 consecutive years ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (BRSE:1CG) with a Buy recommendation. There are 575 funds or institutions reporting positions ...